Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.49 |
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | RAB9A | P51151 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4452382 | 1.00 | NPC1 (0.49) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL4452387 | 1.00 | NPC1 (0.49) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3936797 | 0.86 | NPC1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3934825 | 0.85 | NPC1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3936792 | 0.84 | MAPT (0.46) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3936786 | 0.84 | MAPT (0.46) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3934813 | 0.83 | MAPT (0.46) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3934820 | 0.83 | MAPT (0.46) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL4455466 | 0.80 | MAPT (0.57) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL4455472 | 0.80 | MAPT (0.57) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488353-B2 | Cationic heteroarylazine dyes and colorants containing these compounds | WELLA AG (DE) | 2009-02-10 | — | — | US | claimed |
| US-20070174975-A1 | Cationic heteroarylazine dyes and colorants containing these compounds | Wella GmbH (DE) | 2007-08-02 | — | — | US | claimed |
| US-7488353-B2 | Cationic heteroarylazine dyes and colorants containing these compounds | WELLA AG (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20070174975-A1 | Cationic heteroarylazine dyes and colorants containing these compounds | Wella GmbH (DE) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070174975-A1 | Cationic heteroarylazine dyes and colorants containing these compounds | KRT18, IK, CRYZ | NPC1 3720/4885MAPT 1057/4885RAB9A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.